Oneg HaKarmel Ltd. Is a medical device company that focuses on innovative devices for the Operating Room and for use in Emergency Medicine. The company’s main product is the HemaClear® – Sterile Exsanguination Tourniquet for bloodless surgical field and the HemaShock® for reanimation of critical patients. Several additional products are in the pipeline.
The company excels in conceiving, developing and bringing to market novel products through its extensive network of distributors and Key Opinion Leaders.
Our Goal is to create a platform for implementing advanced physiological principles to provide devices that can improve the outcome of healthcare. We seek to identify clinical needs that are handled by outdated traditional practices and develop solutions that improve patient outcome.
Founder, CEO and CMO – Prof. Noam Gavriely MD and DSc graduate of the Technion Medical School and post-doctorate at the Harvard School of Public Health, with academic career focused on cardio-pulmonary physiology at the Technion and at Northwestern University. Gavriely’s clinical experience is an emergency and ICU physician. In 1996 he founded his first biomedical company – Karmel Medical Acoustic Technologies Ltd. Subsequent Companies were Oneg HaKarmel Ltd.; ETView Ltd, now owned by Ambu; and KarmelSonix Ltd. (now traded on ASX). Gavriely has >80 scientific publications and holds multiple US and international patents.
Manufacturing and Logistics Our products are manufactured in Israel and in China. They are shipped from three logistics centers in Haifa, Amsterdam and California. Strict validation and verification, with extra-tight QC, facilitate impeccable safety track record, with over 1.5 million products distributed in 48 countries and used in leading hospitals on 5 continents.
Regulatory and Quality
Oneg HaKarmel is ISO 13845 certified to develop and manufacture medical devices. The HemaClear® has CE Mark certification (Class Is) through MedCert Notified Body. The products are FDA listed (Class I) and certified by CFDA (China), TFDA (Taiwan), Anvisa (Brazil), AMAR (Israel), TGA (Australia) as well as in Russia, Argentina, Mexico and Japan. The product was endorsed by NICE (UK) based on the many peer-reviewed studies published about its use.